IndustryCompany release

Quantum BioPharma extends Unbuzzd loan to 2027 and delists Class B shares from CSE

Quantum Biopharma Ltd. (QNTM) · Thu 12 Nov 2026

In its third-quarter MD&A, the company reported a deferred-interest loan extension to licensee Unbuzzd, a cancelled warrant, a larger equity stake and a Nasdaq-only listing.

Quantum BioPharma has amended its loan to licensee Unbuzzd Wellness, pushing maturity out to 31 December 2027 and deferring interest, according to its management's discussion and analysis for the quarter and nine months ended 30 September 2026. The document is dated 12 November 2026.

As part of the arrangement, Quantum cancelled the anti-dilution warrant certificate previously held by Unbuzzd. The company also subscribed for 1.5 million Unbuzzd shares at C$0.20 each in a private placement, lifting its holding in the licensee to 19.87%.

On the corporate side, Quantum's Class B shares left the Canadian Securities Exchange (CSE) on 4 September 2026. The shares remain listed on Nasdaq.

The MD&A also notes that the company's lead asset, Lucid-MS for multiple sclerosis, is still at the preclinical stage. No further development timelines or data were provided in the information available to VigiEye.

What it means for your team

  • Quantum's lead programme, Lucid-MS, remains preclinical, so no regulatory submissions are implied by this update.
  • The Unbuzzd loan now runs to the end of 2027 with interest deferred, and Quantum's equity stake has risen to 19.87%; teams tracking licensing partners may wish to note the changed terms.
  • Quantum's Class B shares now trade only on Nasdaq following the CSE delisting on 4 September 2026.

Company's press release (SEC filing): Quantum Biopharma Ltd. ↗

Article written by VigiEye from the official source (Quantum Biopharma Ltd.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →